Molecular dynamic simulation insights into the normal state and restoration of p53 function

International Journal of Molecular Sciences

Volumn 13, Issue 8, 2012, Pages 9709-9740

  Fu, Ting ^a,b,c   Min, Hanyi ^d   Xu, Yong ^e   Chen, Jianzhong ^f   Li, Guohui ^a  

^a DALIAN INSTITUTE OF CHEMICAL PHYSICS   (China)

^b DALIAN UNIVERSITY OF TECHNOLOGY   (China)

^c UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^d PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^e GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH   (China)

^f SHANDONG JIAOTONG UNIVERSITY   (China)

Author keywords

Conformational change; MDM2; MDMX; Molecular dynamic simulation; P53; Protein ligand interaction; Protein protein interaction

Indexed keywords

PROTEIN INHIBITOR; PROTEIN MDM2; PROTEIN MDMX; PROTEIN P53;

CANCER INHIBITION; CANCER PREVENTION; CARBOXY TERMINAL SEQUENCE; CELL CYCLE; DRUG DESIGN; DRUG DEVELOPMENT; GENE DELETION; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR DYNAMICS; NONHUMAN; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; REVIEW; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; METABOLISM;

ANIMALS; DRUG DESIGN; HUMANS; MODELS, MOLECULAR; MOLECULAR DYNAMICS SIMULATION; PROTEIN CONFORMATION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84865045039     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms13089709     Document Type: Review

References (173)

1. DeLeo, A.B.; Jay, G.; Appella, E.; Dubois, G.C.; Law, L.W.; Old, L.J. Detection of a transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse. Proc. Natl. Acad. Sci. USA 1979, 76, 2420-2424.
2. Rodier, F.; Campisi, J.; Bhaumik, D. Two faces of p53: Aging and tumor suppression. Nucleic Acids Res. 2007, 35, 7475-7484.
3. Teodoro, J.G.; Evans, S.K.; Green, M.R. Inhibition of tumor angiogenesis by p53: A new role for the guardian of the genome. J. Mol. Med. (Berl.) 2007, 85, 1175-1186.
4. Vousden, K.H.; Lane, D.P. P53 in health and disease. Nat. Rev. Mol. Cell Biol. 2007, 8, 275-283.
5. Vazquez, A.; Bond, E.E.; Levine, A.J.; Bond, G.L. The genetics of the p53 pathway, apoptosis and cancer therapy. Nat. Rev. Drug Discov. 2008, 7, 979-987.
6. Kastan, M.B.; Onyekwere, O.; Sidransky, D.; Vogelstein, B.; Craig, R.W. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 1991, 51, 6304-6311.
7. Pustisek, N.; Situm, M. UV-radiation, apoptosis and skin. Coll. Antropol. 2011, 35, 339-341.
8. Campbell, H.G.; Mehta, R.; Neumann, A.A.; Rubio, C.; Baird, M.; Slatter, T.L.; Braithwaite, A.W. Activation of p53 following ionizing radiation, but not other stressors, is dependent on the proline-rich domain (PRD). Oncogene 2012, doi:10.1038/onc.2012.102.
9. Pennica, D.; Goeddel, D.V.; Hayflick, J.S.; Reich, N.C.; Anderson, C.W.; Levine, A.J. The amino acid sequence of murine p53 determined from a c-DNA clone. Virology 1984, 134, 477-482.
10. Pavletich, N.P.; Chambers, K.A.; Pabo, C.O. The DNA-binding domain of p53 contains the four conserved regions and the major mutation hot spots. Genes Dev. 1993, 7, 2556-2564.
11. Walker, K.K.; Levine, A.J. Identification of a novel p53 functional domain that is necessary for efficient growth suppression. Proc. Natl. Acad. Sci. USA 1996, 93, 15335-15340.
12. Joerger, A.C.; Fersht, A.R. Structure-function-rescue: The diverse nature of common p53 cancer mutants. Oncogene 2007, 26, 2226-2242.
13. Cho, Y.; Gorina, S.; Jeffrey, P.D.; Pavletich, N.P. Crystal structure of a p53 tumor suppressor-DNA complex: Understanding tumorigenic mutations. Science 1994, 265, 346-355.
14. Kitayner, M.; Rozenberg, H.; Rohs, R.; Suad, O.; Rabinovich, D.; Honig, B.; Shakked, Z. Diversity in DNA recognition by p53 revealed by crystal structures with Hoogsteen base pairs. Nat. Struct. Mol. Biol. 2010, 17, 423-429.
15. Chen, Y.; Dey, R.; Chen, L. Crystal structure of the p53 core domain bound to a full consensus site as a self-assembled tetramer. Structure 2010, 18, 246-256.
16. Lee, W.; Harvey, T.S.; Yin, Y.; Yau, P.; Litchfield, D.; Arrowsmith, C.H. Solution structure of the tetrameric minimum transforming domain of p53. Nat. Struct. Biol. 1994, 1, 877-890.
17. Bell, S.; Klein, C.; Müller, L.; Hansen, S.; Buchner, J. P53 contains large unstructured regions in its native state. J. Mol. Biol. 2002, 322, 917-927.
18. Kussie, P.H.; Gorina, S.; Marechal, V.; Elenbaas, B.; Moreau, J.; Levine, A.J.; Pavletich, N.P. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 1996, 274, 948-953.
19. Rustandi, R.R.; Baldisseri, D.M.; Weber, D.J. Structure of the negative regulatory domain of p53 bound to S100B(betabeta). Nat. Struct. Biol. 2000, 7, 570-574.
20. The PyMOL Molecular Graphics System, Version 1.2r3pre. DeLano Scientific: San Carlos, CA, USA. Available online: http://pymol.org (accessed on 1 January 2012).
21. Sakaguchi, K.; Herrera, J.E.; Saito, S.; Miki, T.; Bustin, M.; Vassilev, A.; Anderson, C.W.; Appella, E. DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes Dev. 1998, 12, 2831-2841.
22. Warnock, L.J.; Knox, A.; Mee, T.R.; Raines, S.A.; Milner, J. Influence of tetramerisation on site-specific post-translational modifications of p53: Comparison of human and murine p53 tumor suppressor protein. Cancer Biol. Ther. 2008, 7, 1481-1489.
23. Scoumanne, A.; Chen, X. Protein methylation: A new mechanism of p53 tumor suppressor regulation. Histol. Histopathol. 2008, 23, 1143-1149.
24. Taira, N.; Yoshida, K. Post-translational modifications of p53 tumor suppressor: Determinants of its functional targets. Histol. Histopathol. 2012, 27, 437-443.
25. Murray, J.K.; Gellman, S.H. Targeting protein-protein interactions: Lessons from p53/MDM2. Biopolymers 2007, 88, 657-686.
26. Tzakos, A.G.; Fokas, D.; Johannes, C.; Moussis, V.; Hatzimichael, E.; Briasoulis, E. Targeting oncogenic protein-protein interactions by diversity oriented synthesis and combinatorial chemistry approaches. Molecules 2011, 16, 4408-4427.
27. Popowicz, G.M.; Czarna, A.; Holak, T.A. Structure of the human Mdmx protein bound to the p53 tumor suppressor transactivation domain. Cell Cycle 2008, 7, 2441-2443.
28. Chipuk, J.E.; Bouchier-Hayes, L.; Kuwana, T.; Newmeyer, D.D.; Green, D.R. PUMA couples the nuclear and cytoplasmic proapoptotic function of p53. Science 2005, 309, 1732-1735.
29. Jiang, P.; Du, W.; Heese, K.; Wu, M. The Bad guy cooperates with good cop p53: Bad is transcriptionally up-regulated by p53 and forms a Bad/p53 complex at the mitochondria to induce apoptosis. Mol. Cell. Biol. 2006, 26, 9071-9082.
30. Sattler, M.; Liang, H.; Nettesheim, D.; Meadows, R.P.; Harlan, J.E.; Eberstadt, M.; Yoon, H.S.; Shuker, S.B.; Chang, B.S.; Minn, A.J.; Thompson, C.B.; Fesik, S.W. Structure of Bcl-xL-Bak peptide complex: Recognition between regulators of apoptosis. Science 1997, 275, 983-986.
31. Yamada, T.; Goto, M.; Punj, V.; Zaborina, O.; Chen, M.L.; Kimbara, K.; Majumdar, D.; Cunningham, E.; Gupta, T.K.D.; Chakrabarty, A.M. Bacterial redox protein Azurin, tumor suppressor protein p53, and regression of cancer. Proc. Natl. Acad. Sci. USA 2002, 99, 14098-14103.
32. Punj, V.; Gupta, T.K.D.; Chakrabarty, A.M. Bacterial cupredoxin azurin and its interactions with the tumor suppressor protein p53. Biochem. Biophys. Res. Commun. 2003, 312, 109-114.
33. Yamada, T.; Hiraoka, Y.; Ikehata, M.; Kimbara, K.; Avner, B.S.; Gupta, T.K.D.; Chakrabarty, A.M. Apoptosis or growth arrest: Modulation of tumor suppressor p53's specificity by bacterial redox protein azurin. Proc. Natl. Acad. Sci. USA 2004, 101, 4770-4775.
34. Bochkareva, E.; Kaustov, L.; Ayed, A.; Yi, G.S.; Lu, Y.; Pineda-Lucena, A.; Liao, J.C.; Okorokov, A.L.; Milner, J.; Arrowsmith, C.H.; Bochkarev, A. Single-stranded DNA mimicry in the p53 transactivation domain interaction with replication protein A. Proc. Natl. Acad. Sci. USA 2005, 102, 15412-15417.
35. Di Lello, P.; Jenkins, L.M.; Jones, T.N.; Nguyen, B.D.; Hara, T.; Yamaguchi, H.; Dikeakos, J.D.; Appella, E.; Legault, P.; Omichinski, J.G. Structure of the Tfb1/p53 complex: Insights into the interaction between the p62/Tfb1 subunit of TFIIH and the activation domain of p53. Mol. Cell 2006, 22, 731-740.
36. Lilyestrom, W.; Klein, M.G.; Zhang, R.; Joachimiak, A.; Chen, X.S. Crystal structure of SV40 large T-antigen bound to p53: Interplay between a viral oncoprotein and a cellular tumor suppressor. Genes Dev. 2006, 20, 2373-2382.
37. Ahn, J.; Prives, C. The C-terminus of p53: The more you learn the less you know. Nat. Struct. Biol. 2001, 8, 730-732.
38. Avalos, J.L.; Celic, I.; Muhammad, S.; Cosgrove, M.S.; Boeke, J.D.; Wolberger, C. Structure of a Sir2 enzyme bound to an acetylated p53 peptide. Mol. Cell 2002, 10, 523-535.
39. Mujtaba, S.; He, Y.; Zeng, L.; Yan, S.; Plotnikova, O.; Sachchidanand; Sanchez, R.; Zeleznik-Le, N.J.; Ronai, Z.; Zhou, M.M. Structural mechanism of the bromodomain of the coactivator CBP in p53 transcriptional activation. Mol. Cell 2004, 13, 251-263.
40. Chuikov, S.; Kurash, J.K.; Wilson, J.R.; Xiao, B.; Justin, N.; Ivanov, G.S.; McKinney, K.; Tempst, P.; Prives, C.; Gamblin, S.J.; Barlev, N.A.; Reinberg, D. Regulation of p53 activity through lysine methylation. Nature 2004, 432, 353-560.
41. Lowe, E.D.; Tews, I.; Cheng, K.Y.; Brown, N.R.; Gul, S.; Noble, M.E.; Gamblin, S.J.; Johnson, L.N. Specificity determinants of recruitment peptides bound to phospho-CDK2/cyclin A. Biochemistry 2002, 41, 15625-15634.
42. Greenblatt, M.S.; Bennett, W.P.; Hollstein, M.; Harris, C.C. Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis. Cancer Res. 1994, 54, 4855-4878.
43. Pfeifer, G.P.; Besaratinia, A. Mutational spectra of human cancer. Hum. Genet. 2009, 125, 493-506.
44. Goh, A.M.; Coffill, C.R.; Lane, D.P. The role of mutant p53 in human cancer. J. Pathol. 2011, 223, 116-126.
45. Popowicz, G.M.; Czarna, A.; Wolf, S.; Wang, K.; Wang, W.; Dömling, A.; Holak, T.A. Structures of low molecular weight inhibitors bound to MDMX and MDM2 reveal new approaches for p53-MDMX/MDM2 antagonist drug discovery. Cell Cycle 2010, 9, 1104-1111.
46. Dickens, M.P.; Fitzgerald, R.; Fischer, P.M. Small-molecule inhibitors of MDM2 as new anticancer therapeutics. Semin. Cancer Biol. 2010, 20, 10-18.
47. Pazgier, M.; Liu, M.; Zou, G.; Yuan, W.; Li, C.; Li, C.; Li, J.; Monbo, J.; Zella, D.; Tarasov, S.G.; Lu, W. Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX. Proc. Natl. Acad. Sci. USA 2009, 106, 4665-4670.
48. Phan, J.; Li, Z.; Kasprzak, A.; Li, B.; Sebti, S.; Guida, W.; Schönbrunn, E.; Chen, J. Structure-based design of high affinity peptides inhibiting the interaction of p53 with MDM2 and MDMX. J. Biol. Chem. 2010, 285, 2174-2183.
49. Li, C.; Pazgier, M.; Li, C.; Yuan, W.; Liu, M.; Wei, G.; Lu, W.Y.; Lu, W. Systematic mutational analysis of peptide inhibition of the p53-MDM2/MDMX interactions. J. Mol. Biol. 2010, 398, 200-213.
50. Dudkina, A.S.; Lindsley, C.W. Small molecule protein-protein inhibitors for the p53-MDM2 interaction. Curr. Top. Med. Chem. 2007, 7, 952-960.
51. Zhan, C.; Lu, W. Peptide activators of the p53 tumor suppressor. Curr. Pharm. Des. 2011, 17, 603-609.
52. Hu, C.Q.; Hu, Y.Z. Small molecule inhibitors of the p53-MDM2. Curr. Med. Chem. 2008, 15, 1720-1730.
53. Patel, S.; Player, M.R. Small-molecule inhibitors of the p53-HDM2 interaction for the treatment of cancer. Expert Opin. Investig. Drugs 2008, 17, 1865-1882.
54. Riedinger, C.; McDonnell, J.M. Inhibitors of MDM2 and MDMX: A structural perspective. Future Med. Chem. 2009, 1, 1075-1094.
55. Millard, M.; Pathania, D.; Grande, F.; Xu, S.; Neamati, N. Small-molecule inhibitors of p53-MDM2 interaction: The 2006-2010 update. Curr. Pharm. Des. 2011, 17, 536-559.
56. Vu, B.T.; Vassilev, L. Small-molecule inhibitors of the p53-MDM2 interaction. Curr. Top. Microbiol. Immunol. 2011, 348, 151-172.
57. Popowicz, G.M.; Dömling, A.; Holak, T.A. The structure-based design of Mdm2/Mdmx-p53 inhibitors gets serious. Angew. Chem. Int. Ed. Engl. 2011, 50, 2680-2688.
58. Joerger, A.C.; Fersht, A.R. The tumor suppressor p53: From structures to drug discovery. Cold Spring Harb. Perspect. Biol. 2010, 2, doi:10.1101/cshperspect.a000919.
59. Vassilev, L.T.; Vu, B.T.; Graves, B.; Carvajal, D.; Podlaski, F.; Filipovic, Z.; Kong, N.; Kammlott, U.; Lukacs, C.; Klein, C.; Fotouhi, N.; Liu, E.A. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004, 303, 844-848.
60. Grasberger, B.L.; Lu, T.; Schubert, C.; Parks, D.J.; Carver, T.E.; Koblish, H.K.; Cummings, M.D.; LaFrance, L.V.; Milkiewicz, K.L.; Calvo, R.R., et al. Discovery and cocrystal structure of benzodiazepinedione HDM2 antagonists that activate p53 in cells. J. Med. Chem. 2005, 48, 909-912.
61. Baek, S.; Kutchukian, P.S.; Verdine, G.L.; Huber, R.; Holak, T.A.; Lee, K.W.; Popowicz, G.M. Structure of the stapled p53 peptide bound to Mdm2. J. Am. Chem. Soc. 2012, 134, 103-106.
62. Rustandi, R.R.; Drohat, A.C.; Baldisseri, D.M.; Wilder, P.T.; Weber, D.J. The Ca(2+)-dependent interaction of S100B(betabeta) with a peptide derived from p53. Biochemistry 1998, 37, 1951-1960.
63. Delphin, C.; Ronjat, M.; Deloulme, J.C.; Garin, G.; Debussche, L.; Higashimoto, Y.; Sakaguchi, K.; Baudier, J. Calcium-dependent interaction of S100B with the C-terminal domain of the tumor suppressor p53. J. Biol. Chem. 1999, 274, 10539-10544.
64. Markowitz, J.; MacKerell, A.D., Jr.; Weber, D.J. A search for inhibitors of S100B, a member of the S100 family of calcium-binding proteins. Mini Rev. Med. Chem. 2007, 7, 609-616.
65. Chen, J.; Zhang, S.; Liu, X.; Zhang, Q. Insights into drug resistance of mutations D30N and I50V to HIV-1 protease inhibitor TMC-114: Free energy calculation and molecular dynamic simulation. J. Mol. Model. 2010, 16, 459-468.
66. Haupt, Y.; Maya, R.; Kazaz, A.; Oren, M. Mdm2 promotes the rapid degradation of p53. Nature 1997, 387, 296-299.
67. Lane, D.P.; Hall, P.A. MDM2-arbiter of p53's destruction. Trends Biochem. Sci. 1997, 22, 372-374.
68. Moll, U.M.; Petrenko, O. The MDM2-p53 interaction. Mol. Cancer Res. 2003, 1, 1001-1008.
69. Brooks, C.L.; Gu, W. p53 ubiquitination: Mdm2 and beyond. Mol. Cell 2006, 21, 307-315.
70. Shvarts, A.; Steegenga, W.T.; Riteco, N.; van Laar, T.; Dekker, P.; Bazuine, M.; van Ham, R.C.; van der Houven van Oordt, W.; Hateboer, G.; van der Eb, A.J.; Jochemsen, A.G. MDMX: A novel p53-binding protein with some functional properties of MDM2. EMBO J. 1996, 15, 5349-5357.
71. Mancini, F.; Moretti, F. Mitochondrial MDM4 (MDMX): An unpredicted role in the p53-mediated intrinsic apoptotic pathway. Cell Cycle 2009, 8, 3854-3859.
72. Toledo, F.; Wahl, G.M. Regulating the p53 pathway: In vitro hypotheses, in vivo veritas. Nat. Rev. Cancer 2006, 6, 909-923.
73. Brown, C.J.; Cheok, C.F.; Verma, C.S.; Lane, D.P. Reactivation of p53: From peptides to small molecules. Trends Pharmacol. Sci. 2011, 32, 53-62.
74. Lee, S.H.; Park, B.J. P53 activation by blocking Snail: A novel pharmacological strategy for cancer. Curr. Pharm. Des. 2011, 17, 610-617.
75. Kalid, O.; Ben-Tal, N. Study of MDM2 binding to p53-analogues: Affinity, helicity, and applicability to drug design. J. Chem. Inf. Model. 2009, 49, 865-876.
76. Espinoza-Fonseca, L.M. Leucine-rich hydrophobic clusters promote folding of the N-terminus of the intrinsically disordered transactivation domain of p53. FEBS Lett. 2009, 583, 556-560.
77. Dastidar, S.G.; Lane, D.P.; Verma, C.S. Multiple peptide conformations give rise to similar binding affinities: Molecular simulations of p53-MDM2. J. Am. Chem. Soc. 2008, 130, 13514-13515.
78. Macchiarulo, A.; Giacchè, N.; Carotti, A.; Baroni, M.; Cruciani, G.; Pellicciari, R. Targeting the conformational transitions of MDM2 and MDMX: Insights into dissimilarities and similarities of p53 recognition. J. Chem. Inf. Model. 2008, 48, 1999-2009.
79. Lauria, A.; Tutone, M.; Ippolito, M.; Pantano, L.; Almerico, A.M. Molecular modeling approaches in the discovery of new drugs for anti-cancer therapy: The investigation of p53-MDM2 interaction and its inhibition by small molecules. Curr. Med. Chem. 2010, 17, 3142-3154.
80. Espinoza-Fonseca, L.M.; Trujillo-Ferrara, J.G. Conformational changes of the p53-binding cleft of MDM2 revealed by molecular dynamics simulations. Biopolymers 2006, 83, 365-373.
81. Terakawa, T.; Takada, S. Multiscale ensemble modeling of intrinsically disordered proteins: P53 N-terminal domain. Biophys. J. 2011, 101, 1450-1458.
82. Xiong, K.; Zwier, M.C.; Myshakina, N.S.; Burger, V.M.; Asher, S.A.; Chong, L.T. Direct observations of conformational distributions of intrinsically disordered p53 peptides using UV Raman and explicit solvent simulations. J. Phys. Chem. A 2011, 115, 9520-9527.
83. Espinoza-Fonseca, L.M.; Trujillo-Ferrara, J.G. Transient stability of the helical pattern of region F19-L22 of the N-terminal domain of p53: A molecular dynamics simulation study. Biochem. Biophys. Res. Commun. 2006, 343, 110-116.
84. Mavinahalli, J.N.; Madhumalar, A.; Beuerman, R.W.; Lane, D.P.; Verma, C. Differences in the transactivation domains of p53 family members: A computational study. BMC Genomics 2010, 11, doi:10.1186/1471-2164-11-S1-S5.
85. Lai, Z.; Auger, K.R.; Manubay, C.M.; Copeland, R.A. Thermodynamics of p53 binding to hdm2(1-126): Effects of phosphorylation and p53 peptide length. Arch. Biochem. Biophys. 2000, 381, 278-284.
86. Lee, H.J.; Srinivasan, D.; Coomber, D.; Lane, D.P.; Verma, C.S. Modulation of the p53-MDM2 interaction by phosphorylation of Thr18: A computational study. Cell Cycle 2007, 6, 2604-2611.
87. Brown, C.J.; Srinivasan, D.; Jun, L.H.; Coomber, D.; Verma, C.S.; Lane, D.P. The electrostatic surface of MDM2 modulates the specificity of its interaction with phosphorylated and unphosphorylated p53 peptides. Cell Cycle 2008, 7, 608-610.
88. Dastidar, S.G.; Lane, D.P.; Verma, C.S. Modulation of p53 binding to MDM2: Computational studies reveal important roles of Tyr100. BMC Bioinforma. 2009, 10, doi:10.1186/1471-2105- 10-S15-S6.
89. Dastidar, S.G.; Madhumalar, A.; Fuentes, G.; Lane, D.P.; Verma, C.S. Forces mediating protein-protein interactions: A computational study of p53 "approaching" MDM2. Theor. Chem. Acc. 2010, 125, 621-635.
90. Carotti, A.; Macchiarulo, A.; Giacchè, N.; Pellicciari, R. Targeting the conformational transitions of MDM2 and MDMX: Insights into key residues affecting p53 recognition. Proteins 2009, 77, 524-535.
91. Brown, C.J.; Dastidar, S.G.; Quah, S.T.; Lim, A.; Chia, B.; Verma, C.S. C-terminal substitution of MDM2 interacting peptides modulates binding affinity by distinctive mechanisms. PLoS One 2011, 6, doi:10.1371/journal.pone.0024122.
92. Dastidar, S.G.; Raghunathan, D.; Nicholson, J.; Hupp, T.R.; Lane, D.P.; Verma, C.S. Chemical states of the N-terminal "lid" of MDM2 regulate p53 binding: Simulations reveal complexities of modulation. Cell Cycle 2011, 10, 82-89.
93. Bharatham, N.; Chi, S-W.; Yoon, H.S. Molecular Basis of Bcl-XL-p53 Interaction: Insights from Molecular Dynamics Simulations. PLoS One 2011, 6, doi:10.1371/journal.pone.0026014.
94. Taranta, M.; Bizzarri, A.R.; Cannistraro, S. Modeling the interaction between the N-terminal domain of the tumor suppressor p53 and azurin. J. Mol. Recognit. 2009, 22, 215-222.
95. Duan, J.; Nilsson, L. Effect of Zn2+ on DNA recognition and stability of the p53 DNA-binding domain. Biochemistry 2006, 45, 7483-7492.
96. Wang, T.; Shao, X.; Cai, W.; Xue, Y.; Wang, S.; Feng, X. Predicting the coordination geometry for Mg2+ in the p53 DNA-binding domain: Insights from computational studies. Phys. Chem. Chem. Phys. 2011, 13, 1140-1151.
97. De Grandis, V.; Bizzarri, A.R.; Cannistraro, S. Docking study and free energy simulation of the complex between p53 DNA-binding domain and azurin. J. Mol. Recognit. 2007, 20, 215-226.
98. Santini, S.; Bizzarri, A.R.; Cannistraro, S. Modelling the interaction between the p53 DNA-binding domain and the p28 peptide fragment of Azurin. J. Mol. Recognit. 2011, 24, 1043-1055.
99. Chène, P. The role of tetramerization in p53 function. Oncogene 2001, 20, 2611-2617.
100. Jeffrey, P.D.; Gorina, S.; Pavletich, N.P. Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms. Science 1995, 267, 1498-1502.
101. Mittl, P.R.; Chène, P.; Grütter, M.G. Crystallization and structure solution of p53 (residues 326-356) by molecular replacement using an NMR model as template. Acta Crystallogr. D 1998, 54, 86-89.
102. Chong, L.T.; Snow, C.D.; Rhee, Y.M.; Pande, V.S. Dimerization of the p53 oligomerization domain: Identification of a folding nucleus by molecular dynamics simulations. J. Mol. Biol. 2005, 345, 869-878.
103. Duan, J.; Nilsson, L. Thermal unfolding simulations of a multimeric protein-transition state and unfolding pathways. Proteins 2005, 59, 170-182.
104. Galea, C.; Bowman, P.; Kriwacki, R.W. Disruption of an intermonomer salt bridge in the p53 tetramerization domain results in an increased propensity to form amyloid fibrils. Protein Sci. 2005, 14, 2993-3003.
105. Lubin, D.J.; Butler, J.S.; Loh, S.N. Folding of tetrameric p53: Oligomerization and tumorigenic mutations induce misfolding and loss of function. J. Mol. Biol. 2010, 395, 705-716.
106. Lwin, T.Z.; Durant, J.J.; Bashford, D. A fluid salt-bridging cluster and the stabilization of p53. J. Mol. Biol. 2007, 373, 1334-1347.
107. Baudier, J.; Delphin, C.; Grunwald, D.; Khochbin, S.; Lawrence, J.J. Characterization of the tumor suppressor protein p53 as a protein kinase C substrate and a S100b-binding protein. Proc. Natl. Acad. Sci. USA 1992, 89, 11627-11631.
108. Fernandez-Fernandez, M.R.; Veprintsev, D.B.; Fersht, A.R. Proteins of the S100 family regulate the oligomerization of p53 tumor suppressor. Proc. Natl. Acad. Sci. USA 2005, 102, 4735-4740.
109. Fernandez-Fernandez, M.R.; Rutherford, T.J.; Fersht, A.R. Members of the S100 family bind p53 in two distinct ways. Protein Sci. 2008, 17, 1663-1670.
110. Van Dieck, J.; Fernandez-Fernandez, M.R.; Veprintsev, D.B.; Fersht, A.R. Modulation of the oligomerization state of p53 by differential binding of proteins of the S100 family to p53 monomers and tetramers. J. Biol. Chem. 2009, 284, 13804-13811.
111. Rustandi, R.R.; Baldisseri, D.M.; Drohat, A.C.; Weber, D.J. Structural changes in the C- terminus of Ca2+-bound rat S100B (beta beta) upon binding to a peptide derived from the C-terminal regulatory domain of p53. Protein Sci. 1999, 8, 1743-1751.
112. Lin, J.; Blake, M.; Tang, C.; Zimmer, D.; Rustandi, R.R.; Weber, D.J.; Carrier, F. Inhibition of p53 transcriptional activity by the S100B calcium-binding protein. J. Biol. Chem. 2001, 276, 35037-35041.
113. Chen, J. Intrinsically disordered p53 extreme C-terminus binds to S100B(betabeta) through "fly-casting". J. Am. Chem. Soc. 2009, 131, 2088-2089.
114. Wilder, P.T.; Lin, J.; Bair, C.L.; Charpentier, T.H.; Yang, D.; Liriano, M.; Varney, K.M.; Lee, A.; Oppenheim, A.B.; Adhya, S.; Carrier, F.; Weber, D.J. Recognition of the tumor suppressor protein p53 and other protein targets by the calcium-binding protein S100B. Biochim. Biophys. Acta 2006, 1763, 1284-1297.
115. Drohat, A.C.; Baldisseri, D.M.; Rustandi, R.R.; Weber, D.J. Solution structure of calcium-bound rat S100B(betabeta) as determined by nuclear magnetic resonance spectroscopy. Biochemistry 1998, 37, 2729-2740.
116. Deichmann, M.; Benner, A.; Bock, M.; Jäckel, A.; Uhl, K.; Waldmann, V.; Näher, H. S100-Beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma. J. Clin. Oncol. 1999, 17, 1891-1896.
117. Jäckel, A.; Deichmann, M.; Waldmann, V.; Bock, M.; Näher, H. S-100 beta protein in serum, a tumor marker in malignant melanoma-current state of knowledge and clinical experience. Hautarzt 1999, 50, 250-256.
118. Harpio, R.; Einarsson, R. S100 proteins as cancer biomarkers with focus on S100B in malignant melanoma. Clin. Biochem. 2004, 37, 512-518.
119. Gieldon, A.; Mori, M.; Del Conte, R. Theoretical study on binding of S100B protein. J. Mol. Model. 2007, 13, 1123-1131.
120. Allen, W.J.; Capelluto, D.G.; Finkielstein, C.V.; Bevan, D.R. Modeling the relationship between the p53 C-terminal domain and its binding partners using molecular dynamics. J. Phys. Chem. B 2010, 114, 13201-13213.
121. Pirolli, D.; Alinovi, C.C.; Capoluongo, E.; Satta, M.A.; Concolino, P.; Giardina, B.; de Rosa, M.C. Insight into a novel p53 single point mutation (G389E) by molecular dynamics simulations. Int. J. Mol. Sci. 2010, 12, 128-140.
122. Tang, Y.; Zhao, W.; Chen, Y.; Zhao, Y.; Gu, W. Acetylation is indispensable for p53 activation. Cell 2008, 133, 612-626.
123. Scolnick, D.M.; Chehab, N.H.; Stavridi, E.S.; Lien, M.C.; Caruso, L.; Moran, E.; Berger, S.L.; Halazonetis, T.D. CREB-binding protein and p300/CBP-associated factor are transcriptional coactivators of the p53 tumor suppressor protein. Cancer Res. 1997, 57, 3693-3696.
124. Livengood, J.A.; Scoggin, K.E.; Van Orden, K.; McBryant, S.J.; Edayathumangalam, R.S.; Laybourn, P.J.; Nyborg, J.K. P53 Transcriptional activity is mediated through the SRC1-interacting domain of CBP/p300. J. Biol. Chem. 2002, 277, 9054-9061.
125. Okoshi, R.; Ando, K.; Suenaga, Y.; Sang, M.; Kubo, N.; Kizaki, H.; Nakagawara, A.; Ozaki, T. Transcriptional regulation of tumor suppressor p53 by cAMP-responsive element-binding protein/AMP-activated protein kinase complex in response to glucose deprivation. Genes Cells 2009, 14, 1429-1440.
126. Sachchidanand; Resnick-Silverman, L.; Yan, S.; Mutjaba, S.; Liu, W.J.; Zeng, L.; Manfredi, J.J.; Zhou, M.M. Target structure-based discovery of small molecules that block human p53 and CREB binding protein association. Chem. Biol. 2006, 13, 81-90.
127. Borah, J.C.; Mujtaba, S.; Karakikes, I.; Zeng, L.; Muller, M.; Patel, J.; Moshkina, N.; Morohashi, K.; Zhang, W.; Gerona-Navarro, G.; Hajjar, R.J.; Zhou, M.M. A small molecule binding to the coactivator CREB-binding protein blocks apoptosis in cardiomyocytes. Chem. Biol. 2011, 18, 531-541.
128. Gerona-Navarro, G.; Yoel-Rodríguez; Mujtaba, S.; Frasca, A.; Patel, J.; Zeng, L.; Plotnikov, A.N.; Osman, R.; Zhou, M.M. Rational design of cyclic peptide modulators of the transcriptional coactivator CBP: A new class of p53 inhibitors. J. Am. Chem. Soc. 2011, 133, 2040-2043.
129. Eichenbaum, K.D.; Rodríguez, Y.; Mezei, M.; Osman, R. The energetics of the acetylation switch in p53-mediated transcriptional activation. Proteins 2010, 78, 447-456.
130. Chandrasekaran, R.; Thompson, M. Polybromo-1-bromodomains bind histone H3 at specific acetyl-lysine positions. Biochem. Biophys. Res. Commun. 2007, 355, 661-666.
131. Lavu, S.; Boss, O.; Elliott, P.J.; Lambert, P.D. Sirtuins-novel therapeutic targets to treat age-associated diseases. Nat. Rev. Drug Discov. 2008, 7, 841-853.
132. Milne, J.C.; Denu, J.M. The Sirtuin family: Therapeutic targets to treat diseases of aging. Curr. Opin. Chem. Biol. 2008, 12, 11-17.
133. Vaziri, H.; Dessain, S.K.; Eaton, E.N.; Imai, S.I.; Frye, R.A.; Pandita, T.K.; Guarente, L.; Weinberg, R.A. HSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 2001, 107, 149-159.
134. Luo, J.; Nikolaev, A.Y.; Imai, S.; Chen, D.; Su, F.; Shiloh, A.; Guarente, L.; Gu, W. Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell 2001, 107, 137-148.
135. Langley, E.; Pearson, M.; Faretta, M.; Bauer, U.M.; Frye, R.A.; Minucci, S.; Pelicci, P.G.; Kouzarides, T. Human SIR2 deacetylates p53 and antagonizes PML/p53-induced cellular senescence. EMBO J. 2002, 21, 2383-2396.
136. Smith, J. Human Sir2 and the 'silencing' of p53 activity. Trends Cell Biol. 2002, 12, 404-406.
137. Ivanov, G.S.; Ivanova, T.; Kurash, J.; Ivanov, A.; Chuikov, S.; Gizatullin, F.; Herrera-Medina, E.M.; Rauscher, F.; Reinberg, D.; Barlev, N.A. Methylation-acetylation interplay activates p53 in response to DNA damage. Mol. Cell. Biol. 2007, 27, 6756-6769.
138. Zhang, X.; Bruice, T.C. Mechanism of product specificity of AdoMet methylation catalyzed by lysine methyltransferases: Transcriptional factor p53 methylation by histone lysine methyltransferase SET7/9. Biochemistry 2008, 47, 2743-2748.
139. Bai, Q.; Shen, Y.; Yao, X.; Wang, F.; Du, Y.; Wang, Q.; Jin, N.; Hai, J.; Hu, T.; Yang, J. Modeling a new water channel that allows SET9 to dimethylate p53. PLoS One 2011, 6, doi:10.1371/journal.pone.0019856.
140. Ding, Y.; Mei, Y.; Zhang, J.Z. Quantum mechanical studies of residue-specific hydrophobic interactions in p53-MDM2 binding. J. Phys. Chem. B 2008, 112, 11396-11401.
141. Hu, G.; Wang, D.; Liu, X.; Zhang, Q. A computational analysis of the binding model of MDM2 with inhibitors. J. Comput. Aided Mol. Des. 2010, 24, 687-697.
142. Ding, K.; Lu, Y.; Nikolovska-Coleska, Z.; Wang, G.; Qiu, S.; Shangary, S.; Gao, W.; Qin, D.; Stuckey, J.; Krajewski, K.; Roller, P.P.; Wang, S. Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction. J. Med. Chem. 2006, 49, 3432-3435.
143. Chen, J.; Wang, J.; Xu, B.; Zhu, W.; Li, G. Insight into mechanism of small molecule inhibitors of the MDM2-p53 interaction: Molecular dynamics simulation and free energy analysis. J. Mol. Graph. Model. 2011, 30, 46-53.
144. Wang, F.; Li, Y.; Ma, Z.; Wang, X.; Wang, Y. Structural determinants of benzodiazepinedione/peptide-based p53-HDM2 inhibitors using 3D-QSAR, docking and molecular dynamics. J. Mol. Model. 2012, 18, 295-306.
145. Liu, Y.; Lane, D.P.; Verma, C.S. Systematic mutational analysis of an ubiquitin ligase (MDM2)-binding peptide: Computational studies. Theor. Chem. Acc. 2011, 130, 1145-1154.
146. Cheng, W.; Chen, J.; Liang, Z.; Li, G.; Yi, C.; Wang, W.; Wang, K. A computational analysis of interaction mechanisms of peptide and non-peptide inhibitors with MDMX based on molecular dynamics simulation. Comp. Theor. Chem. 2012, 984, 43-50.
147. Barakat, K.; Mane, J.; Friesen, D.; Tuszynski, J. Ensemble-based virtual screening reveals dual-inhibitors for the p53-MDM2/MDMX interactions. J. Mol. Graph. Model. 2010, 28, 555-568.
148. Joseph, T.L.; Madhumalar, A.; Brown, C.J.; Lane, D.P.; Verma, C.S. Differential binding of p53 and nutlin to MDM2 and MDMX: Computational studies. Cell Cycle 2010, 9, 1167-1181.
149. Lu, S.Y.; Jiang, Y.J.; Zou, J.W.; Wu, T.X. Molecular modeling and molecular dynamics simulation studies on pyrrolopyrimidine-based α-helix mimetic as dual inhibitors of MDM2 and MDMX. J. Mol. Graph. Model. 2011, 30, 167-178.
150. Chen, J.; Zhang, D.; Zhang, Y.; Li, G. Computational studies of difference in binding modes of peptide and non-peptide inhibitors to MDM2/MDMX based on molecular dynamics simulations. Int. J. Mol. Sci. 2012, 13, 2176-2195.
151. Bernal, F.; Tyler, A.F.; Korsmeyer, S.J.; Walensky, L.D.; Verdine, G.L. Reactivation of the p53 tumor suppressor pathway by a stapled p53 peptide. J. Am. Chem. Soc. 2007, 129, 2456-2457.
152. Madden, M.M.; Muppidi, A.; Li, Z.; Li, X.; Chen, J.; Lin, Q. Synthesis of cell-permeable stapled peptide dual inhibitors of the p53-Mdm2/Mdmx interactions via photoinduced cycloaddition. Bioorg. Med. Chem. Lett. 2011, 21, 1472-1475.
153. Muppidi, A.; Li, X.; Chen, J.; Lin, Q. Conjugation of spermine enhances cellular uptake of the stapled peptide-based inhibitors of p53-Mdm2 interaction. Bioorg. Med. Chem. Lett. 2011, 21, 7412-7415.
154. Crunkhorn, S. Anticancer drugs: Stapled peptide rescues p53. Nat. Rev. Drug Discov. 2011, 10, doi:10.1038/nrd3342.
155. Guo, Z.; Mohanty, U.; Noehre, J.; Sawyer, T.K.; Sherman, W.; Krilov, G. Probing the alpha-helical structural stability of stapled p53 peptides: Molecular dynamics simulations and analysis. Chem. Biol. Drug Des. 2010, 75, 348-359.
156. Joseph, T.L.; Lane, D.; Verma, C.S. Stapled peptides in the p53 pathway: Computer simulations reveal novel interactions of the staples with the target protein. Cell Cycle 2010, 9, 4560-4568.
157. Lin, J.; Yang, Q.; Yan, Z.; Markowitz, J.; Wilder, P.T.; Carrier, F.; Weber, D.J. Inhibiting S100B restores p53 levels in primary malignant melanoma cancer cells. J. Biol. Chem. 2004, 279, 34071-34077.
158. Lin, J.; Yang, Q.; Wilder, P.T.; Carrier, F.; Weber, D.J. The calcium-binding protein S100B down-regulates p53 and apoptosis in malignant melanoma. J. Biol. Chem. 2010, 285, 27487-27498.
159. Markowitz, J.; Chen, I.; Gitti, R.; Baldisseri, D.M.; Pan, Y.; Udan, R.; Carrier, F.; MacKerell, A.D., Jr.; Weber, D.J. Identification and characterization of small molecule inhibitors of the calcium-dependent S100B-p53 tumor suppressor interaction. J. Med. Chem. 2004, 47, 5085-5093.
160. Markowitz, J.; Mackerell, A.D., Jr.; Carrier, F.; Charpentier, T.H.; Weber, D.J. Design of inhibitors for S100B. Curr. Top. Med. Chem. 2005, 5, 1093-1108.
161. Wilder, P.T.; Charpentier, T.H.; Liriano, M.A.; Gianni, K.; Varney, K.M.; Pozharski, E.; Coop, A.; Toth, E.A.; Mackerell, A.D.; Weber, D.J. In vitro screening and structural characterization of inhibitors of the S100B-p53 interaction. Int. J. High Throughput Screen. 2010, 2010, 109-126.
162. Charpentier, T.H.; Wilder, P.T.; Liriano, M.A.; Varney, K.M.; Zhong, S.; Coop, A.; Pozharski, E.; MacKerell, A.D., Jr.; Toth, E.A.; Weber, D.J. Small molecules bound to unique sites in the target protein binding cleft of calcium-bound S100B as characterized by nuclear magnetic resonance and X-ray crystallography. Biochemistry 2009, 48, 6202-6212.
163. Whitlow, J.L.; Varughese, J.F.; Zhou, Z.; Bartolotti, L.J.; Li, Y. Computational screening and design of S100B ligand to block S100B-p53 interaction. J. Mol. Graph. Model. 2009, 27, 969-977.
164. Zhou, Z.; Li, Y. Molecular dynamics simulation of S100B protein to explore ligand blockage of the interaction with p53 protein. J. Comput. Aided Mol. Des. 2009, 23, 705-714.
165. Tanimura, S.; Ohtsuka, S.; Mitsui, K.; Shirouzu, K.; Yoshimura, A.; Ohtsubo, M. MDM2 interacts with MDMX through their RING finger domains. FEBS Lett. 1999, 447, 5-9.
166. Wang, L.; He, G.; Zhang, P.; Wang, X.; Jiang, M.; Yu, L. Interplay between MDM2, MDMX, Pirh2 and COP1: The negative regulators of p53. Mol. Biol. Rep. 2011, 38, 229-236.
167. Van Dieck, J.; Lum, J.K.; Teufel, D.P.; Fersht, A.R. S100 proteins interact with the N-terminal domain of MDM2. FEBS Lett. 2010, 584, 3269-3274.
168. Wang, M.; Lei, Y. Delaying vascular aging with Chinese medicine: Implications from an overview of the p53 and miR-34s family. Chin. J. Integr. Med. 2011, 17, 635-639.
169. Zhang, X.; Zhao, M.; Chen, L.; Jiao, H.; Liu, H.; Wang, L.; Ma, S. A triterpenoid from Thalictrum fortunei induces apoptosis in BEL-7402 cells through the P53-induced apoptosis pathway. Molecules 2011, 16, 9505-9519.
170. Zhang, F.; Xu, L.; Qu, X.; Zhao, M.; Jin, B.; Kang, J.; Liu, Y.; Hu, X. Synergistic antitumor effect of β-elemene and etoposide is mediated via induction of cell apoptosis and cell cycle arrest in non-small cell lung carcinoma cells. Mol. Med. Rep. 2011, 4, 1189-1193.
171. Wang, X.Y.; Wang, Y.G.; Wang, Y.F. Ginsenoside Rb1, Rg1 and three extracts of traditional Chinese medicine attenuate ultraviolet B-induced G1 growth arrest in HaCaT cells and dermal fibroblasts involve down-regulating the expression of p16, p21 and p53. Photodermatol. Photoimmunol. Photomed. 2011, 27, 203-212.
172. Liu, C.H.; Chen, C.Y.; Huang, A.M.; Li, J.H. Subamolide A, a component isolated from Cinnamomum subavenium, induces apoptosis mediated by mitochondria-dependent, p53 and ERK1/2 pathways in human urothelial carcinoma cell line NTUB1. J. Ethnopharmacol. 2011, 137, 503-511.
173. Nag, S.A.; Qin, J.J.; Wang, W.; Wang, M.H.; Wang, H.; Zhang, R. Ginsenosides as Anticancer Agents: In vitro and in vivo Activities, Structure-Activity Relationships, and Molecular Mechanisms of Action. Front. Pharmacol. 2012, 3, doi:10.3389/fphar.2012.00025.